東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Characterization of the relationship...

Ranji, Cyra M.

FindBook

Google Book

Amazon

博客來

Characterization of the relationship between the IGF-1R tyrosine kinase pathway and the notch signaling pathway with Human Aspartyl (Asparaginyl) beta-hydroxylase (HAAH) in lung cancer cells.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Characterization of the relationship between the IGF-1R tyrosine kinase pathway and the notch signaling pathway with Human Aspartyl (Asparaginyl) beta-hydroxylase (HAAH) in lung cancer cells./
作者:	Ranji, Cyra M.
面頁冊數:	67 p.
附註:	Source: Masters Abstracts International, Volume: 48-06, page: 3496.
Contained By:	Masters Abstracts International48-06.
標題:	Biology, Cell. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=1485372
ISBN:	9781124133942

Characterization of the relationship between the IGF-1R tyrosine kinase pathway and the notch signaling pathway with Human Aspartyl (Asparaginyl) beta-hydroxylase (HAAH) in lung cancer cells.
Ranji, Cyra M.

Characterization of the relationship between the IGF-1R tyrosine kinase pathway and the notch signaling pathway with Human Aspartyl (Asparaginyl) beta-hydroxylase (HAAH) in lung cancer cells. - 67 p.

Source: Masters Abstracts International, Volume: 48-06, page: 3496.

Thesis (M.S.)--Hood College, 2010.

Human Aspartyl-Asparaginyl beta-hydroxylase (HAAH) is highly expressed in many cancer types including hepatocellular carcinoma, cholangiocarcinoma, breast, colon, intestinal, lung, pancreatic, and neuronal cancers. It plays an important role in the cellular transformation and invasive growth of malignant tumors. HAAH is specifically a cell surface antigen found on cancer cells, therefore it is easily accessible. This characteristic makes it a promising drug target for immunotherapy for various cancers because specific cells can be targeted unlike chemotherapy or radiation treatments where all cells are affected. It has been suggested that the IGF-1 pathway is an upstream mediator of HAAH and that HAAH is an upstream mediator of the Notch signaling pathway. In this study effects of the tyrosine kinase inhibitor PPP, or the gamma-secretase inhibitor DBZ on HAAH expression in the H460 lung cancer cell line were investigated. In addition, the effects of a novel drug candidate, anti-HAAH antibody PAN-622, were studied on the IGF-1R and Notch signaling pathways. Drug synergies between PPP and PAN-622 as well as DBZ and PAN-622 were also investigated. The H460 lung cancer cell line was treated with PPP, PAN-622, and DBZ, and tumor cell proliferation was evaluated. All three compounds were successful in blocking proliferation of H460 cells. IGF-1R, HAAH, and Notch protein expression were evaluated using western blot analysis. HAAH and Notch mRNA expression was measured by quantitative real-time PCR. These studies demonstrated that the IGF-1R pathway is likely inactive in untreated H460 cells, but can be up-regulated through inhibition of the Notch pathway. HAAH is an activator of the Notch pathway and its inhibition by the anti-HAAH antibody, PAN-622 results in an inhibition of the Notch pathway.

ISBN: 9781124133942Subjects--Topical Terms:

1017686
Biology, Cell.

Characterization of the relationship between the IGF-1R tyrosine kinase pathway and the notch signaling pathway with Human Aspartyl (Asparaginyl) beta-hydroxylase (HAAH) in lung cancer cells.
LDR:03408nam 2200301 4500 001 1403366
005 20111115085223.5
008 130515s2010 ||||||||||||||||| ||eng d
020 $a 9781124133942
035 $a (UMI)AAI1485372
035 $a AAI1485372
040 $a UMI $c UMI
100 1 $a Ranji, Cyra M. $3 1682622
245 1 0 $a Characterization of the relationship between the IGF-1R tyrosine kinase pathway and the notch signaling pathway with Human Aspartyl (Asparaginyl) beta-hydroxylase (HAAH) in lung cancer cells.
300 $a 67 p.
500 $a Source: Masters Abstracts International, Volume: 48-06, page: 3496.
500 $a Advisers: Craig S. Laufer; Michael S. Lebowitz.
502 $a Thesis (M.S.)--Hood College, 2010.
520 $a Human Aspartyl-Asparaginyl beta-hydroxylase (HAAH) is highly expressed in many cancer types including hepatocellular carcinoma, cholangiocarcinoma, breast, colon, intestinal, lung, pancreatic, and neuronal cancers. It plays an important role in the cellular transformation and invasive growth of malignant tumors. HAAH is specifically a cell surface antigen found on cancer cells, therefore it is easily accessible. This characteristic makes it a promising drug target for immunotherapy for various cancers because specific cells can be targeted unlike chemotherapy or radiation treatments where all cells are affected. It has been suggested that the IGF-1 pathway is an upstream mediator of HAAH and that HAAH is an upstream mediator of the Notch signaling pathway. In this study effects of the tyrosine kinase inhibitor PPP, or the gamma-secretase inhibitor DBZ on HAAH expression in the H460 lung cancer cell line were investigated. In addition, the effects of a novel drug candidate, anti-HAAH antibody PAN-622, were studied on the IGF-1R and Notch signaling pathways. Drug synergies between PPP and PAN-622 as well as DBZ and PAN-622 were also investigated. The H460 lung cancer cell line was treated with PPP, PAN-622, and DBZ, and tumor cell proliferation was evaluated. All three compounds were successful in blocking proliferation of H460 cells. IGF-1R, HAAH, and Notch protein expression were evaluated using western blot analysis. HAAH and Notch mRNA expression was measured by quantitative real-time PCR. These studies demonstrated that the IGF-1R pathway is likely inactive in untreated H460 cells, but can be up-regulated through inhibition of the Notch pathway. HAAH is an activator of the Notch pathway and its inhibition by the anti-HAAH antibody, PAN-622 results in an inhibition of the Notch pathway.
520 $a Our findings have increased the understanding of the relationship between the IGF-1R and Notch pathways with HAAH and may be valuable in understanding the proliferation and survival of H460 cells in vitro. In summary, our results show that PPP, PAN-622, and DBZ are potent inhibitors of malignant cell growth in vitro. PAN-622 is currently in development as a novel therapeutic agent for cancer. These studies further the understanding of the mechanism of action of PAN-622 and the relationship of HAAH to the IGF-1R and Notch pathways.
590 $a School code: 0917.
650 4 $a Biology, Cell. $3 1017686
650 4 $a Health Sciences, Oncology. $3 1018566
690 $a 0379
690 $a 0992
710 2 $a Hood College. $3 1680845
773 0 $t Masters Abstracts International $g 48-06.
790 1 0 $a Laufer, Craig S., $e advisor
790 1 0 $a Lebowitz, Michael S., $e advisor
790 $a 0917
791 $a M.S.
792 $a 2010
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=1485372